Restoration of p53 function leads to tumour regression in vivo

@article{Ventura2007RestorationOP,
  title={Restoration of p53 function leads to tumour regression in vivo},
  author={Andrea Ventura and David G. Kirsch and Margaret E. Mclaughlin and David A. Tuveson and Jan Grimm and Laura Lintault and Jamie J. Newman and Elizabeth E. Reczek and Ralph Weissleder and Tyler Jacks},
  journal={Nature},
  year={2007},
  volume={445},
  pages={661-665}
}
Tumorigenesis is a multi-step process that requires activation of oncogenes and inactivation of tumour suppressor genes. Mouse models of human cancers have recently demonstrated that continuous expression of a dominantly acting oncogene (for example, Hras, Kras and Myc) is often required for tumour maintenance; this phenotype is referred to as oncogene addiction. This concept has received clinical validation by the development of active anticancer drugs that specifically inhibit the function of… 
Restoration of p53 function: A new therapeutic strategy to induce tumor regression?
TLDR
It is indicated that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.
Stage-specific sensitivity to p53 restoration during lung cancer progression
TLDR
It is proposed that p53 not only limits malignant progression by suppressing the acquisition of alterations that lead to tumour progression, but also, in the context of p53 restoration, responds to increased oncogenic signalling to mediate tumour regression.
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
TLDR
It is indicated that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.
Partial p53 reactivation is sufficient to induce cancer regression
TLDR
The observation that a partial loss-of-function p53 variant promotes tumorigenesis in one setting and induces regression in another, underlines the highly context-specific effects of individual p53 mutants and encourages ongoing research efforts into mutant p53 reactivating drugs.
Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy
TLDR
This study provides the first proof-of-principle evidence that p53 inactivation at late stages of tumorigenesis can also generate a vulnerability to p53 reactivation, and suggests the use of Mdm2 inhibitors as ARF mimetics for sensitizing ARF-deficient tumors to p 53-reactivating drugs.
Pharmacological reactivation of p53 as a strategy to treat cancer
TLDR
Recent advances in the development of small molecules that restore the function of mutant p53 by different mechanisms are summarized, including stabilization of its folding by Apr‐246, which is currently being tested in a Phase II clinical trial.
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?
TLDR
Current understanding of the mechanisms by which p53 induces cell death is discussed and how this affects p53-mediated tumour suppression and the response of malignant cells to anticancer therapy is discussed.
Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment
TLDR
It is shown that long-term HSP90 inhibition significantly extends the survival of mutp53 Q/− (R248Q allele) and H/H (R172H allele) mice by 59% and 48%, respectively, but not their corresponding p53−/− littermates, and drug activity correlates with induction ofmutp53 degradation, tumour apoptosis and prevention of T-cell lymphomagenesis.
Contribution of p53 to metastasis.
TLDR
Understanding the mechanisms by which p53 loss and mutation promote tumor metastasis is crucial to understanding the biology of tumor progression and how to appropriately apply targeted therapies.
Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras
  • N. Young, T. Jacks
  • Biology, Medicine
    Proceedings of the National Academy of Sciences
  • 2010
TLDR
Using constitutive and inducible RNAi systems in vivo, cell type-specific chromatin regulation of Ink4a/Arf is highlighted as a critical determinant of cellular responses to oncogenic K-ras.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
TLDR
It is indicated that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.
Essential role for oncogenic Ras in tumour maintenance
TLDR
The results provide genetic evidence that H-RasV12G is important in both the genesis and maintenance of solid tumours, and the failure of persistent endogenous and enforced VEGF expression to sustain tumour viability indicates that the tumour-maintaining actions of activated Ras extend beyond the regulation of V EGF expression in vivo.
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
TLDR
It is demonstrated that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes, raising the possibility that transient in activation ofMYC may be an effective therapy for certain cancers.
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
TLDR
It is shown that the p53-mediated pathological response to whole-body irradiation, a prototypical genotoxic carcinogen, is irrelevant for suppression of radiation-induced lymphoma, and delaying the restoration of p53 function until the acute radiation response has subsided abrogates all of the radiation- induced pathology yet preserves much of the protection from lymphoma.
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
TLDR
This work found one compound capable of inducing apoptosis in human tumor cells through restoration of the transcriptional transactivation function to mutant p53, named PRIMA-1, which rescued both DNA contact and structural p53 mutants in vitro and in living cells.
Temporal dissection of p53 function in vitro and in vivo
TLDR
It is shown here that both tissues in vivo and cells in vitro derived from such mice can be rapidly toggled between wild-type and p53 knockout states, the first example of a new class of genetic model that allows the specific, rapid and reversible perturbation of the function of a single endogenous gene in vivo.
Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide
TLDR
The results suggest that TAT-mediated transduction may be a useful strategy for the therapeutic delivery of large tumor suppressor molecules to malignant cells in vivo and show that specific activation of endogenous p53 activity by a macromolecular agent is therapeutically effective in preclinical models of terminal human malignancy.
Tumor spectrum analysis in p53-mutant mice
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
TLDR
Observations indicate that a normal p53 gene is dispensable for embryonic development, that its absence predisposes the animal to neoplastic disease, and that an oncogenic mutant form of p53 is not obligatory for the genesis of many types of tumours.
...
1
2
3
4
...